Raptor Pharmaceutical Corp Form 3/A February 11, 2014

### FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response...

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement Raptor Pharmaceutical Corp [RPTP] Erbez Georgia (Month/Day/Year) 02/11/2014 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O RAPTOR 09/12/2012 (Check all applicable) **PHARMACEUTICAL** CORP.. 5 HAMILTON 10% Owner Director LANDING, SUITE 160 \_X\_\_ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group Chief Financial Officer Filing(Check Applicable Line) \_X\_ Form filed by One Reporting Person NOVATO, CAÂ 94949 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) (Instr. 5) Form: Direct (D) or Indirect (Instr. 5) Trustee for the benefit of Jake Common Stock I  $1.800^{(1)}$ Phillip Erbez Trustee for the benefit of Common Stock Ι  $1,700 \frac{(1)}{2}$ Alexander D. Erbez Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

#### Edgar Filing: Raptor Pharmaceutical Corp - Form 3/A

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and 3. Title and Amount of **Expiration Date** (Month/Day/Year)

Securities Underlying **Derivative Security** (Instr. 4)

5. Conversion or Exercise Derivative Price of Derivative Security: Security Direct (D)

6. Nature of Indirect Ownership Beneficial Ownership Form of (Instr. 5)

Expiration Date Exercisable Date

Amount or Title Number of Shares

or Indirect (I) (Instr. 5)

### **Reporting Owners**

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer

Other

Erbez Georgia

C/O RAPTOR PHARMACEUTICAL CORP. 5 HAMILTON LANDING, SUITE 160 NOVATO, CAÂ 94949

Â

A Chief Financial Officer A

## **Signatures**

/s/ Mark Jones, Raptor Pharmaceutical Corp., Attorney-in-Fact

02/11/2014

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These shares were omitted from the reporting person's original Form 3, and also were omitted from two Forms 4 filed by the reporting person after the original Form 3 was filed.

Â

#### **Remarks:**

Exhibit 24 - Power of Attorney attached.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2